Evaluation of minimal residual disease,immune cells dynamics and quality of life in bortezomib based induction therapy followed by lenalidomide maintenance for newly diagnosed patients with multiple myeloma ineligible for stem cell transplantation.
Not Applicable
- Conditions
- Multiple Myeloma
- Registration Number
- JPRN-UMIN000014197
- Lead Sponsor
- Kyoto University Hematology Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
patient who is not suitable for taking part in this study from the sight of the physician in charge
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method